Goldline Pharmaceutical Ltd Management Discussions

Company Overview:

Goldline Pharmaceutical Limited is engaged in the pharmaceutical sector, focusing on the development, manufacturing, marketing, and distribution of pharmaceutical products. The Company remains committed to delivering quality healthcare solutions by adhering to established quality standards and regulatory requirements.

The Company operates in a competitive pharmaceutical environment and continues to focus on strengthening its operational capabilities, improving efficiency, and expanding its market presence. With increasing healthcare awareness and growing demand for quality medicines, the Company aims to capitalize on emerging opportunities while maintaining sustainable growth.

The Company continues to emphasize quality, compliance, customer satisfaction, and efficient resource utilization as key drivers for long-term value creation.

Financial Performance:

During FY 2025 26, the Company delivered improved operational and financial performance. The key financial highlights are as follows:

Sr. No Particulars	FY 2025 26 (INR	FY 2024 25 (INR
	Lakhs)	Lakhs)
1 Revenue from Operations and Other	Rs. 3,119.88	Rs. 2,805.57
Income
2 Profit Before Interest, Depreciation and	Rs. 694.13	Rs. 583.21
Tax (EBITDA)
3 Profit Before Tax	Rs. 538.54	Rs. 385.84
4 Net Profit After Tax	Rs. 411.71	Rs. 283.43
5 Basic Earnings Per Share ( )	Rs. 5.97	Rs. 4.11
6 Diluted Earnings Per Share ( )	Rs. 5.97	Rs. 4.11

The Company has demonstrated steady improvement in financial performance during FY 2025 26. Revenue increased from INR 2,805.57 Lakhs in FY 2024 25 to INR 3,119.88 Lakhs during the year under review, reflecting growth in business operations.

The Profit After Tax increased to INR 411.71 Lakhs compared to INR 283.43 Lakhs in the previous year, supported by improved operational efficiency, effective cost management, and better utilization of resources.

Internal Control System and Their Adequacy:

The Company has established a comprehensive internal control framework commensurate with the size and nature of its operations. The internal control systems are designed to ensure:

- Accuracy and reliability of financial reporting.

- Safeguarding of assets.

- Compliance with applicable statutory and regulatory requirements.

- Effective monitoring of operational performance. Key features of the internal control framework include:

- Regular review of financial and operational controls.

- Periodic internal audits and management reviews.

- Proper authorization and approval mechanisms for financial transactions.

- Continuous monitoring of compliance requirements.

The Company periodically evaluates and strengthens its internal control systems to ensure effectiveness and alignment with changing business and regulatory requirements.

Opportunities and Threats:

Opportunities:

- Increasing demand for pharmaceutical and healthcare products.

- Growth opportunities arising from rising healthcare awareness and expenditure.

- Expansion into new geographical markets.

- Adoption of advanced technologies and improved manufacturing practices.

- Opportunities arising from government initiatives supporting the pharmaceutical sector.

- Increasing focus on affordable and quality healthcare solutions.

Threats:

- Intense competition within the pharmaceutical industry.

- Regulatory changes and increasing compliance requirements.

- Pricing pressures due to competitive market conditions.

- Dependence on raw material availability and supply chain stability.

- Fluctuations in input costs.

- Changes in domestic and global healthcare policies.

Segment-wise or Product-wise Performance:

The Company operates in a single business segment, i.e., pharmaceutical products and related activities.

The financial performance of the Company during FY 2025 26 compared with FY 2024 25 is summarized below:

Particulars	Year Ended 31.03.2026	Year Ended 31.03.2025
Revenue from Operations and	3,119.88	2,805.57
Other Income
Profit Before Interest,	694.13	583.21
Depreciation and Tax
Less: Finance Cost	131.46	172.34
Less: Depreciation and	24.13	25.03
Amortization
Profit Before Exceptional Items	538.54	385.84
and Tax
Exceptional Items	Nil	Nil
Profit Before Tax	538.54	385.84
Current Tax Expense	143.43	99.14
Deferred Tax Asset/(Liability)	16.60	(3.27)
Net Profit After Tax	411.71	283.43
Basic Earnings Per Share ( )	5.97	4.11
Diluted Earnings Per Share ( )	5.97	4.11

Dividend and Reserves:

- Proposed Dividend: NIL

- Transfer to General Reserve: INR 411.71 Lakhs

- Surplus carried to Balance Sheet: INR 411.71 Lakhs

The Board of Directors continues to adopt a prudent approach towards retaining earnings to support future growth and strengthen the financial position of the Company.

Earnings per Equity Share:

- Basic EPS: 5.97

- Diluted EPS: 5.97

The improvement in EPS reflects the growth in profitability achieved during FY 2025 26.

Financial Performance Analysis:

The Company has registered strong financial growth during FY 2025 26 as compared with the previous financial year.

Key highlights are as follows:

- Revenue from operations and other income increased to INR 3,119.88 Lakhs from INR 2,805.57 Lakhs in FY 2024 25, reflecting growth of approximately 11.20%.

- Profit Before Tax increased to INR 538.54 Lakhs from INR 385.84 Lakhs, registering growth of approximately 39.57%.

- Net Profit After Tax increased significantly to INR 411.71 Lakhs from INR 283.43 Lakhs, registering growth of approximately 45.27%.

- Earnings Per Share improved from 4.11 in FY 2024 25 to 5.97 in FY 2025 26.

The improved performance reflects the Companys focus on operational efficiency, cost optimization, and sustainable business growth.

Human Resources and Industrial Relations:

Employees remain an important contributor to the Companys success. The Company recognizes the importance of skilled and committed employees and continues to focus on:

- Employee development and skill enhancement.

- Maintaining a positive and productive work environment.

- Encouraging employee engagement and teamwork.

- Ensuring harmonious industrial relations.

The Company believes that a motivated workforce plays a significant role in achieving operational excellence and long-term growth objectives.

Key Financial Ratios and Variance Analysis:

The key financial ratios of the Company for the financial year ended 31 March 2026 as compared with the previous financial year are as follows:

Sr. No Ratio	FY 2025 26	FY 2024 25	% Change	Remarks
1 Current Ratio	2.15	1.98	8.78%	Improvement in liquidity position due to better management of current assets and current liabilities.
2 Debt Equity Ratio	1.04	1.52	-31.55%	Reduction indicates lower financial leverage and improved debt-equity position.
3 Debt Service Coverage Ratio	2.04	1.46	39.30%	Improvement reflects enhanced ability of the Company to service its debt obligations through operating earnings.
4 Return on Equity (ROE)	37.33%	36.08%	3.47%	Marginal improvement due to increase in profitability during the year.
5 Inventory Turnover Ratio	1.44	1.51	-4.85%	Slight decline due to comparatively lower inventory movement during the year.
6 Trade Receivables Turnover Ratio	2.33	2.76	-15.78%	Reduction indicates a higher receivable holding period and requires continued focus on collection efficiency.
7 Net Capital Turnover Ratio	2.24	2.44	-8.30%	Decline due to increase in working capital employed compared to sales growth.
8 Net Profit Ratio	13.20%	10.10%	30.63%	Significant improvement due to higher profitability and effective cost management.
9 Return on Capital Employed (ROCE)	39.98%	38.70%	3.29%	Improvement indicates better utilization of capital employed for generating returns.
10 Interest Coverage Ratio	5.35	3.20	67.12%	Significant improvement due to higher earnings available to meet finance costs.
11 Trade Payable Turnover Ratio	5.44	5.45	-0.24%	Ratio remained stable, indicating consistent management of supplier payments.

Overall, the Company has maintained a healthy financial position during FY 2025 26. Improvement in profitability ratios, debt servicing capacity, and capital efficiency reflects effective financial management and operational performance. The management continues to monitor working capital efficiency, receivable management, and cost optimization to support sustainable growth.

Conclusion:

Goldline Pharmaceutical Limited has demonstrated strong operational performance and financial growth during FY 2025 26. The Company has achieved improvement in revenue, profitability, and earnings per share through effective operational management and disciplined financial practices.

With increasing demand for healthcare products, focus on quality, and continuous improvement in business processes, the Company is well positioned to pursue sustainable growth opportunities.

Going forward, the management remains focused on strengthening operational capabilities, improving market presence, enhancing efficiency, and creating long-term value for shareholders and stakeholders.